Meta-analysis of Genetic Modifiers Reveals Candidate Dysregulated Pathways in Amyotrophic Lateral Sclerosis. (1st January 2019)

• Record Type: Journal Article
• Authors: Yanagi, Katherine S.; Wu, Zhijin; Amaya, Joshua; Chapkis, Natalie; Duffy, Amanda M.; Hajdarovic, Kaitlyn H.; Held, Aaron; Mathur, Arjun D.; Russo, Kathryn; Ryan, Veronica H.; Steinert, Beatrice L.; Whitt, Joshua P.; Fallon, Justin R.; Fawzi, Nicolas L.; Lipscombe, Diane; Reenan, Robert A.; Wharton, Kristi A.; Hart, Anne C.
• Is Part Of: Neuroscience. Volume 396(2019)
• Page Start: A3
• Page End: A20
• Publication Date: 2019-01-01
• Subjects: ALS Amyotrophic Lateral Sclerosis -- C9orf72 chromosome 9 open-reading frame 72 -- fALS familial ALS -- FTD frontotemporal dementia -- FUS fused in sarcoma -- OPTN optineurin -- sALS sporadic ALS -- SOD1 superoxide dismutase 1 -- TDP43 TAR DNA binding protein 43 -- VCP valosin-containing protein -- VAPB Vesicle-Associated Membrane Protein-Associated Protein B/C; ALS -- FTD -- genetic modifiers -- pathway analysis; Neurochemistry -- Periodicals; Neurophysiology -- Periodicals; Neurology -- Periodicals; Neurochimie -- Périodiques; Neurophysiologie -- Périodiques; Neurochemistry; Neurophysiology; Electronic journals; Periodicals; Electronic journals; 612.8
• DOI: 10.1016/j.neuroscience.2018.10.033
• Languages: English
• ISSNs: 0306-4522

Abstract

Highlights: Genetic modifiers contribute to phenotypic variability of ALS. Created a comprehensive list of known ALS genetic modifiers. Bioinformatic analysis and shared genetic modifiers' results connect ALS-causal genes. Pathological mechanisms underlying ALS may be revealed using this approach. Abstract: Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that has significant overlap with frontotemporal dementia (FTD). Mutations in specific genes have been identified that can cause and/or predispose patients to ALS. However, the clinical variability seen in ALS patients suggests that additional genes impact pathology, susceptibility, severity, and/or progression of the disease. To identify molecular pathways involved in ALS, we undertook a meta-analysis of published genetic modifiers both in patients and in model organisms, and undertook bioinformatic pathway analysis. From 72 published studies, we generated a list of 946 genes whose perturbation (1) impacted ALS in patient populations, (2) altered defects in laboratory models, or (3) modified defects caused by ALS gene ortholog loss of function. Herein, these are all called modifier genes. We found 727 modifier genes that encode proteins with human orthologs. Of these, 43 modifier genes were identified as modifiers of more than one ALS gene/model, consistent with the hypothesis that shared genes and pathways may underlie ALS. Further, we used a gene ontology-based bioinformatic analysis to identify pathways and associated genes that may be important in ALS. To our knowledge this is the first comprehensive survey of ALS modifier genes. This work suggests that shared molecular mechanisms may underlie pathology caused by different ALS disease genes. Surprisingly, few ALS modifier genes have been tested in more than one disease model. Understanding genes that modify ALS-associated defects will help to elucidate the molecular pathways that underlie ALS and provide additional targets for therapeutic intervention.